These controversial results probably reflect the sum of technical issues related to immunohistochemistry staining and scoring system, as well as to biologic issues related to PD-L1 expression on other cells present in the tumor microenvironment, including infiltrating myeloid cells. The gene discussed is CD274; the disease is neoplasm.